Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Anal Bioanal Chem ; 414(24): 7167-7177, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35953725

RESUMEN

Therapeutic peptides are a fast-growing class of pharmaceuticals. Like small molecules, the costs associated with their discovery and development are significant. In addition, since the preclinical data guides first-in-human studies, there is a need for analytical techniques that accelerate and improve our understanding of the absorption, distribution, metabolism, and excretion (ADME) characteristics of early drug candidates. Mass spectrometry imaging (MSI), which can be used to visualize drug distribution in intact tissue, has been extensively used to study small molecule drugs, but only applied to a limited extent to larger molecules, such as peptides, after dosing. Herein, we use MSI to obtain spatial information on the distribution and metabolism of a peptide drug. The immunosuppressant cyclosporine (CsA), a cyclic undecapeptide, was used as a-proof-of-concept peptide and investigated by desorption electrospray ionization (DESI) MSI. Calibration curves were made based on a spiked tissue homogenate model. Different washing protocols were tested to improve sensitivity, but CsA, being a quite lipophilic peptide, was found not to benefit from tissue washing. The distribution of CsA and its metabolites were mapped in whole-body mouse sections and within rat organs. Whole-body DESI-MSI studies in mice showed widespread distribution of CsA with highest abundance in organs like the pancreas and liver. After 24 h, hydroxy and dihydroxy metabolites of CsA were detected predominantly in the intestines, which were largely devoid of CsA. In addition to the DESI-MSI experiments, MALDI-MSI was also conducted on rat jejunum at higher spatial resolution, revealing the morphology of the jejenum at greater detail; however, DESI provided similar results for drug and metabolite distribution in rat jejunum at apparent slightly better sensitivity. Given its label-free nature, MSI could provide valuable ADME insight, especially for candidates in the early-stage pipeline before radiolabeling.


Asunto(s)
Ciclosporina , Espectrometría de Masa por Ionización de Electrospray , Animales , Humanos , Inmunosupresores , Ratones , Preparaciones Farmacéuticas , Ratas , Espectrometría de Masa por Ionización de Electrospray/métodos , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción/métodos , Distribución Tisular
2.
J Pharmacokinet Pharmacodyn ; 45(2): 215-233, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29170989

RESUMEN

The inhibitory effect of anti-obesity drugs on energy intake (EI) is counter-acted by feedback regulation of the appetite control circuit leading to drug tolerance. This complicates the design and interpretation of EI studies in rodents that are used for anti-obesity drug development. Here, we investigated a synthetic long-acting analogue of the appetite-suppressing peptide hormone amylin (LAMY) in lean and diet-induced obese (DIO) rats. EI and body weight (BW) were measured daily and LAMY concentrations in plasma were assessed using defined time points following subcutaneous administration of the LAMY at different dosing regimens. Overall, 6 pharmacodynamic (PD) studies including a total of 173 rats were considered in this evaluation. Treatment caused a dose-dependent reduction in EI and BW, although multiple dosing indicated the development of tolerance over time. This behavior could be adequately described by a population model including homeostatic feedback of EI and a turnover model describing the relationship between EI and BW. The model was evaluated by testing its ability to predict BW loss in a toxicology study and was utilized to improve the understanding of dosing regimens for obesity therapy. As such, the model proved to be a valuable tool for the design and interpretation of rodent studies used in anti-obesity drug development.


Asunto(s)
Peso Corporal/efectos de los fármacos , Ingestión de Energía/efectos de los fármacos , Polipéptido Amiloide de los Islotes Pancreáticos/farmacología , Polipéptido Amiloide de los Islotes Pancreáticos/farmacocinética , Animales , Fármacos Antiobesidad/farmacocinética , Fármacos Antiobesidad/farmacología , Dieta Alta en Grasa/métodos , Femenino , Masculino , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Ratas , Ratas Sprague-Dawley , Ratas Wistar
3.
Diabetes Obes Metab ; 20(1): 60-68, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-28598027

RESUMEN

AIM: To investigate the effects of the novel glucose-dependent insulinotropic polypeptide (GIP) analogue, ZP4165, on body weight and glycaemic control in rodents, and to investigate if ZP4165 modulates the anti-obesity and anti-hyperglycaemic effects of a glucagon-like peptide-1 (GLP-1) agonist (liraglutide). METHODS: The acute insulinotropic effect of ZP4165 was investigated in rats during an oral glucose tolerance test. The long-term effects of ZP4165 on body weight and glycaemic control, either alone or in combination with liraglutide, were assessed in diet-induced obese mice and diabetic db/db mice. RESULTS: ZP4165 showed insulinotropic action in rats. The GIP analogue did not alter the body weight of obese mice but enhanced GLP-1-induced weight loss. In diabetic mice, 4 weeks' dosing with ZP4165 reduced glycated haemoglobin levels vs vehicle by an extent similar to the GLP-1 agonist. CONCLUSIONS: ZP4165 potentiated the anti-obesity effect of a GLP-1 agonist in obese mice and improved glycaemic control in diabetic mice. These studies support further investigation of dual-incretin therapy as a more effective treatment option than mono GLP-1 medication for type 2 diabetes mellitus and obesity.


Asunto(s)
Fármacos Antiobesidad/uso terapéutico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Polipéptido Inhibidor Gástrico/análogos & derivados , Polipéptido Inhibidor Gástrico/uso terapéutico , Hiperglucemia/prevención & control , Hipoglucemiantes/uso terapéutico , Obesidad/tratamiento farmacológico , Receptores de la Hormona Gastrointestinal/agonistas , Animales , Fármacos Antiobesidad/sangre , Fármacos Antiobesidad/farmacocinética , Fármacos Antiobesidad/farmacología , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/metabolismo , Diseño de Fármacos , Quimioterapia Combinada , Polipéptido Inhibidor Gástrico/farmacocinética , Polipéptido Inhibidor Gástrico/farmacología , Receptor del Péptido 1 Similar al Glucagón/agonistas , Receptor del Péptido 1 Similar al Glucagón/genética , Receptor del Péptido 1 Similar al Glucagón/metabolismo , Células HEK293 , Semivida , Humanos , Hipoglucemiantes/sangre , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Incretinas/farmacología , Incretinas/uso terapéutico , Liraglutida/farmacología , Liraglutida/uso terapéutico , Masculino , Ratones Endogámicos C57BL , Ratones Mutantes , Obesidad/sangre , Obesidad/metabolismo , Ratas Sprague-Dawley , Receptores de la Hormona Gastrointestinal/genética , Receptores de la Hormona Gastrointestinal/metabolismo , Receptores de Glucagón/genética , Receptores de Glucagón/metabolismo , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Pérdida de Peso/efectos de los fármacos
4.
Anal Chem ; 83(19): 7388-93, 2011 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-21827175

RESUMEN

The present paper describes a flexible thin layer electrochemical flow cell for ultrasensitive amperometric detection at a supported interface between immiscible electrolyte solutions. Nanomolar detection limits were demonstrated using the cell design, and 3D finite element simulations allowed a detailed characterization of the flow cell. The cell design employed in the present work allowed the sensing oil membrane and the aqueous reference electrode to be placed in close contact, thereby minimizing cell resistance. The adjustable cell volume means that the same cell design can be used for different application with different requirement for detection limits and dynamic range. A disposable membrane was employed which reduces the need for surface cleaning and prevents sample carryover between different applications. For the lowest cell volumes the detection chamber approaches a thin layer electrochemical flow cell detector with a large surface to volume ratio.


Asunto(s)
Técnicas Electroquímicas/métodos , Análisis de Inyección de Flujo/métodos , Técnicas Electroquímicas/instrumentación , Electrólitos/química , Éteres/química , Análisis de Inyección de Flujo/instrumentación , Membranas Artificiales , Polivinilos/química , Soluciones , Propiedades de Superficie , Agua/química
6.
Acta Biomater ; 6(10): 3936-46, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20417734

RESUMEN

Magneto-resistive sensors capable of detecting superparamagnetic micro-/nano-sized beads are promising alternatives to standard diagnostic assays based on absorbance or fluorescence and streptavidin-functionalized beads are widely used as an integral part of these sensors. Here we have developed an immunomicroarray for systematic studies of the binding properties of 10 different micro-/nano-sized streptavidin-functionalized beads to a biotin substrate immobilized on SiO(2) with or without surface modification. SiO(2) surface cleaning, immobilized substrate concentration and surface blocking conditions were optimized. Polyethylene glycol-based surfaces with different end groups on the anchor molecule, 2,4,6-trichloro-1,3,5-triazine (TsT), were synthesized and compared with the standard (3-aminopropyl)triethoxysilane (APTS)/glutaraldehyde chemistry. APTS/glutaraldehyde, directly linked TsT and bare H(2)O(2)-activated SiO(2) performed better than polyethylene glycol-modified surfaces. Two beads, Masterbeads and M-280 beads, were found to give superior results compared with other bead types. Antibody/antigen interactions, illustrated by C-reactive protein, were best performed with Masterbeads. The results provide important information concerning the surface binding properties of streptavidin-functionalized beads and the immunomicroarray can be used when optimizing the performance of bead-based biosensors.


Asunto(s)
Inmunoensayo/métodos , Magnetismo , Análisis por Micromatrices/métodos , Microesferas , Técnicas Biosensibles , Biotina/química , Biotina/metabolismo , Proteína C-Reactiva/metabolismo , Ensayo de Materiales , Estructura Molecular , Polietilenglicoles/química , Albúmina Sérica Bovina/metabolismo , Dióxido de Silicio/química , Estreptavidina/química , Estreptavidina/metabolismo , Propiedades de Superficie
7.
J Phys Chem B ; 113(20): 7263-9, 2009 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-19397256

RESUMEN

The description and understanding of noncovalent interactions and distribution of potential new drug compounds in an organism is of paramount importance for the successful development of new drugs. In this work, a new procedure based on electrochemistry at the interface between two immiscible electrolyte solutions (ITIES) for addressing and discriminating between drug compound/ligand interactions in aqueous solution and nonspecific ligand effects on oil-water distribution behavior has been developed. The procedure is demonstrated using five drug compounds with different physical chemical parameters and alpha-cyclodextrin as the aqueous phase ligand. Alpha-cyclodextrin was chosen as an aqueous phase ligand, as it is frequently used in drug formulations to enhance solubility and bioavailability of drug compounds. Supplementary capillary electrophoresis experiments provided more detailed information on alpha-cyclodextrin drug complexation and, in combination with the electrochemical studies, provided information on solvation effects affecting the oil-water distribution of the drug compounds. The use of ligand shift ion partition diagrams for data presentation is a convenient format for the visualization of ligand effects on distribution behavior of related drug compounds.


Asunto(s)
Electrólitos/química , Preparaciones Farmacéuticas/química , alfa-Ciclodextrinas/química , Electroquímica , Concentración de Iones de Hidrógeno , Soluciones , Agua/química
8.
Anal Chem ; 80(1): 203-8, 2008 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-18052132

RESUMEN

The description and understanding of absorption and distribution of potential new drug compounds in the organism is of paramount importance for the successful development of new drugs. However, the currently used physical chemical parameters such as oil-water distribution coefficients and ionization constants frequently fall short when it comes to a detailed description of the highly heterogeneous environments of both lipophilic and hydrophilic characters through which the drug compound passes. In this work, a new procedure based on electrochemistry at the interface between immiscible electrolyte solutions for addressing drug compound-ligand interactions in lipophilic environments as well as nonspecific ligand effects on distribution behavior has been developed. An attractive feature of the method is that it can simultaneously provide data for oil-water partition coefficients and ionization constants. The new procedure is demonstrated using five drug compounds with different physical chemical parameters and cholesterol as the oil-phase ligand. The use of ligand shift ion partition diagrams in the data presentation allows a quick visualization and comparison of a series of related drug compounds.


Asunto(s)
Electrólitos/química , Interacciones Hidrofóbicas e Hidrofílicas , Tampones (Química) , Colesterol/química , Diflunisal/química , Electroquímica , Lidocaína/química , Ligandos , Prilocaína/química , Propranolol/química , Soluciones , Warfarina/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA